ClearPoint Neuro price target raised to $28 from $20 at B. Riley

B. Riley raised the firm’s price target on ClearPoint Neuro (CLPT) to $28 from $20 and keeps a Buy rating on the shares following a transfer of coverage. ClearPoint is a medical device company focused on providing image-guided navigation for minimally invasive neuro procedures, the analyst tells investors in a research note. The firm says the company’s core business continues to grow over 20% annually, and that it expects significant growth in the future as biopharma partnerships progress towards regulatory approvals and commercial launches.